Generate and Zealand Team Up on AI-Designed Protein Drugs for Metabolic Disease
Generate Biomedicines and Zealand Pharma have formed a multi-target partnership to create multispecific protein therapies for obesity and other metabolic conditions. Generate will receive $30 million upfront, up to $35 million in early preclinical milestones, and as much as nearly $1.2 billion in total milestones plus royalties for two initial programs. The deal expands Zealand's work beyond peptides and brings Generate's AI platform into metabolic disease.
Generate Biomedicines, a clinical-stage company based in Somerville, Massachusetts, will lead research through selection of a lead candidate using its platform, which pairs computational design with large-scale biological experiments. Zealand Pharma, headquartered in Copenhagen, will then handle clinical trials, regulatory filings, and global commercialization.
The arrangement covers two initial programs, with an option for a third. Generate receives $30 million upfront, up to $35 million in early preclinical milestones, and up to roughly $1.2 billion in total milestones plus tiered royalties. Zealand's chief scientific officer said the deal adds proteins to its existing small-molecule and peptide work.
If the partnership yields candidates, patients with obesity and related metabolic conditions could gain access to therapies combining multiple biological actions in one molecule — an approach that may improve convenience or effectiveness where current options fall short. Zealand's move beyond peptides could diversify its pipeline, while Generate's entry into metabolic disease may validate its AI platform for broader drug classes. Success remains uncertain, since AI-designed proteins must still prove safe and effective in human trials, and milestone payments depend on reaching those stages.